Voluntary Licensing Agreement

Some articles and reports constitute several existing voluntary licences for medicines (MSF Access Campaign 2017; Amin 2007). A 2016 WHO report shows that voluntary licensing has significantly lowered the prices of sofosbuvir and discusses the conditions that must be met to enable a competitive market under a voluntary licensing agreement (World Health Organization (WHO) 2016). When rights holders grant voluntary, non-exclusive licences for patented medicines, they allow other manufacturers to develop generic versions of those medicines. This helps to promote competition, support supply, increase accessibility and improve access. What makes it a best practice? As in 2016, Gilead`s licensing approach remains a good practice among companies rated by the index. Dolutegravir or DTG, first approved in 2013 by the U.S. Food & Drug Administration, is now recommended by the World Health Organization as a preferential treatment for HIV. The agreements aimed to make it more affordable for countries with the highest levels of HIV infection, including Kenya, Malawi, South Africa and Tanzania. BARCELONA – In 2014, ViiV Healthcare, a pharmaceutical company committed to ending the HIV epidemic, and Medicines Patent Pool, an organization primarily funded by Unitaid to improve access to medicines in low-income countries, signed two voluntary licensing agreements. .